Holen Sie sich die Stockscreener-App
0.7699
2.06%
-0.0162
Vorhandelsmarkt:
.75
-0.0199
-2.58%
Schlusskurs vom Vortag:
$0.7861
Offen:
$0.7855
24-Stunden-Volumen:
2.48M
Relative Volume:
0.34
Marktkapitalisierung:
$8.26M
Einnahmen:
$5.75M
Nettoeinkommen (Verlust:
$-38.96M
KGV:
-0.0617
EPS:
-12.47
Netto-Cashflow:
$-32.63M
1W Leistung:
-16.77%
1M Leistung:
+5.32%
6M Leistung:
-83.76%
1J Leistung:
-88.08%
1-Tages-Spanne:
$0.71
$0.8049
1-Wochen-Bereich:
$0.71
$1.72
52-Wochen-Spanne:
$0.6076
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Firmenname
Kala Bio Inc
Sektor
Branche
Telefon
781-996-5252
Adresse
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Vergleichen Sie KALA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.7699 | 8.43M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-30 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-09-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-09-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2025-09-08 | Eingeleitet | Mizuho | Outperform |
| 2025-07-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-03-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-14 | Herabstufung | Jefferies | Buy → Hold |
| 2020-07-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-27 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-09 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Kala Bio Inc Aktie (KALA) Neueste Nachrichten
Top Penny Stocks To ResearchDecember 4th - MarketBeat
Kala Bio Shares Jump After $6 Million Funding Deal With Investor David Lazar - MSN
KALA BIO Raises $10M in Direct Offering - TipRanks
KALA BIO closes $10 million registered direct offering By Investing.com - Investing.com India
KALA BIO Raises $10 Million From Direct Offering - marketscreener.com
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - The Manila Times
KALA BIO (NASDAQ: KALA) completes $10 million offering of 10,000,000 shares to repay debt - Stock Titan
Will KALA BIO Inc. stock continue upward momentumMarket Risk Summary & Community Consensus Picks - Newser
Kala Bio raises $10 million in registered direct offering By Investing.com - Investing.com Nigeria
KALA BIO Stock (NASDAQ: KALA): New $10 Million Offering, Debt Deal and Delisting Risk – December 4, 2025 Update - ts2.tech
KALA BIO, Inc. (KALA) Stock: Surges 21.62% Amid Exciting New Offering Announcement - parameter.io
KALA Bio (KALA) Announces $10 Million Direct Stock Offering - GuruFocus
KALA BIO (KALA) Stock Explodes on Oxford Deal and $10M Offering: What December 4, 2025 Means for Investors - ts2.tech
Kala Bio announces $10 mln registered direct offering of common stock - marketscreener.com
Kala Bio Reports $10 Million Direct Stock Offering; Shares Rise - marketscreener.com
Kala Bio raises $10 million in registered direct offering - Investing.com
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - The Manila Times
KALA BIO Announces $10 Million Registered Direct Offering - GlobeNewswire
KALA BIO (NASDAQ: KALA) prices $10M registered direct sale of 10M shares at $1.00 - Stock Titan
KALA Bio’s Bold Move: A New Dawn? - timothysykes.com
Aug Mood: Will KALA BIO Inc stock continue upward momentumTrade Analysis Report & AI Driven Stock Price Forecasts - BỘ NỘI VỤ
KALA BIO raises $10M in direct offering - MSN
Why Did KALA BIO Shares Jump Over 22% After Hours? - Benzinga
Will KALA BIO Inc. stock split attract more investors2025 Analyst Calls & Detailed Earnings Play Strategies - Newser
Is KALA BIO Inc. stock a buy before product launchesJuly 2025 Intraday Action & Daily Stock Trend Reports - Newser
No data: Challenges Affecting KALA Stock Movements - StocksToTrade
An analyst sees good growth prospects for Kala Bio Inc (KALA) - Setenews
KALA BIO's $6M Leadership Turnaround Boosts Shares - Mena FN
KALA BIO Inc. (KALA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kala Bio secures $6 million investment as CEO changes amid trial failure By Investing.com - Investing.com Australia
KALA Stock Soars: Buying Opportunity? - StocksToTrade
KALA BIO, Inc. (KALA) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Crude Oil Gains Over 1%; ISM Manufacturing PMI Falls In November - Benzinga
Dow Dips 200 Points; Q32 Bio Shares Jump - Benzinga
Kala Bio stock soars after $6M investment from David Lazar By Investing.com - Investing.com Nigeria
KALA’s Unexpected Surge: Unpacking the Recent Spike - timothysykes.com
Kala Bio enters into $6 million securities purchase agreement with investor David E. Lazar - marketscreener.com
KALA Secures $6M Investment, Appoints New CEO - GuruFocus
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar - The Manila Times
KALA BIO, Inc. Announces $6 Million Securities Purchase Agreement and Appointment of David E. Lazar as CEO - Quiver Quantitative
KALA BIO (NASDAQ: KALA) inks $6M securities deal, appoints David Lazar CEO and chair - Stock Titan
KALA BIO plunges 92% after phase 2 failure of eye condition drug - MSN
Is Kala Bio Inc (KALA) positioned for future growth? - Setenews
Kala Bio Stock Soars 22% After Hours As Emergency Financing Deal Averts Asset Seizure After Eye Disease Drug Trial Collapse - Stocktwits
[Form 3] KALA BIO, Inc. Initial Statement of Beneficial Ownership - Stock Titan
KALA (KALA BIO) CEO discloses sizable convertible preferred stake - Stock Titan
What Sparked KALA BIO's Nearly 38% Surge Overnight? - Benzinga
Critical Review: REGENXBIO (NASDAQ:RGNX) versus KALA BIO (NASDAQ:KALA) - Defense World
Finanzdaten der Kala Bio Inc-Aktie (KALA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):